balversa market size forecast and market insight

“BALVERSA Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about BALVERSA for Urothelial Carcinoma (UCC) in the seven major markets. A detailed picture of the BALVERSA for UCC in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the BALVERSA for UCC. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BALVERSA market forecast analysis for UCC in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in UCC.

Drug Summary

BALVERSA (erdafitinib) is a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) which has susceptible FGFR3 or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Erdafitinib works by binding and inhibiting the enzymatic activity of FGFR1, FGFR2, FGFR3, and FGFR4. It binds to RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT, and VEGFR2. Erdafitinib inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdafitinib demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer. Balversa is specifically indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUCC) that has susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the BALVERSA description, mechanism of action, dosage and administration, research and development activities in Urothelial Carcinoma (UCC).
• Elaborated details on BALVERSA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BALVERSA research and development activities in UCC across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around BALVERSA.
• The report contains forecasted sales of BALVERSA for UCC till 2032.
• Comprehensive coverage of the late-stage emerging therapies for UCC.
• The report also features the SWOT analysis with analyst views for BALVERSA in UCC.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BALVERSA Analytical Perspective by DelveInsight

In-depth BALVERSA Market Assessment

This report provides a detailed market assessment of BALVERSA for Urothelial Carcinoma (UCC) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

BALVERSA Clinical Assessment

The report provides the clinical trials information of BALVERSA for Urothelial Carcinoma (UCC) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Urothelial Carcinoma (UCC) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BALVERSA dominance.
• Other emerging products for UCC are expected to give tough market competition to BALVERSA and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BALVERSA in UCC.
• Our in-depth analysis of the forecasted sales data of BALVERSA from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BALVERSA in UCC. 

Key Questions

• What is the product type, route of administration and mechanism of action of BALVERSA?
• What is the clinical trial status of the study related to BALVERSA in Urothelial Carcinoma (UCC) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BALVERSA development?
• What are the key designations that have been granted to BALVERSA for UCC?
• What is the forecasted market scenario of BALVERSA for UCC?
• What are the forecasted sales of BALVERSA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to BALVERSA for UCC?
• Which are the late-stage emerging therapies under development for the treatment of UCC?"